The firm is pursuing regulatory clearance for multiple tests and is targeting growth in an attractive CLIA market, a move that will require new hires.

The research may lay the groundwork for a noninvasive test for GI or other types of cancer without prior knowledge of which organ is affected.

The increased revenue was driven by growth in the firm's commercial clinical business.

New product revenues more than doubled year over year, while infectious disease test revenues grew 35 percent. 

The license was issued to the firm's distribution partner, Xcelris Labs, and Epistem intends to begin placing its Genedrive molecular platforms in the coming months.

Method for detecting and distinguishing infectious norovirus from inactivated norovirus
Apparatus and method for a continuous rapid thermal cycle system
Detection of methylated DNA
Method for isolation of nucleic acids and a kit thereof
Setting of multiple priming oligonucleotides for solid gel amplification in hydrogels
Methods for generating target-specific probes for solution-based capture